Experimental Hematology
Volume 30, Issue 10 , Pages 1219-1226 , October 2002

Sensitivity of myeloid leukemia cells to calcium influx blockade: Application to bone marrow purging

  • Jonathan Soboloff

      Affiliations

    • AIDRC, University Health Network and the Department of Immunology, University of Toronto, Toronto, Ontario, Canada
    • The first two authors contributed equally to this work.
    • ,
  • Yicheng Zhang

      Affiliations

    • AIDRC, University Health Network and the Department of Immunology, University of Toronto, Toronto, Ontario, Canada
    • The first two authors contributed equally to this work.
    • ,
  • Mark Minden

      Affiliations

    • Ontario Cancer Institute, University Health Network and Departments of Medicine and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Stuart A Berger

      Affiliations

    • Corresponding Author InformationOffprint requests to: Stuart A. Berger, Ph.D., AIDRC, University Health Network, 620 University Avenue, Suite 700, Toronto, Ontario, Canada, M5G 2M9
    • AIDRC, University Health Network and the Department of Immunology, University of Toronto, Toronto, Ontario, Canada

Received 26 November 2001 ,Revised 14 June 2002 ,Accepted 17 June 2002.

References 

  1. Philip T, Guglielmi C, Hagenbeek A, et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540
  2. Attal M, Harousseau JL, Stoppa AM, et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91
  3. Gorin NC, Aegerter P, Auvert B, et al.  Autologous bone marrow transplantation for acute myelocytic leukemia in first remission (a European survey of the role of marrow purging). Blood. 1990;75:1606
  4. Baynes RD, Hamm C, Dansey R, et al.  Bone marrow and peripheral blood hematopoietic stem cell transplantation (focus on autografting). Clin Chem. 2000;46:1239
  5. Reiffers J, Labopin M, Sanz M, et al.  Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission (an EBMT retrospective analysis). Bone Marrow Transplant. 2000;25:1115
  6. Miller CB, Rowlings PA, Zhang MJ, et al.  The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol. 2001;29:1336
  7. Zittoun RA, Mandelli F, Willemze R, et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217
  8. Brenner MK, Rill DR, Moen RC, et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341:85
  9. Meloni G, Diverio D, Vignetti M, et al.  Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission (prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene). Blood. 1997;90:1321
  10. Herve P, Cahn JY, Plouvier E, et al.  Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results. Invest New Drugs. 1984;2:245
  11. Kaizer H, Chow HS. Autologous bone marrow transplantation (ABMT) in the treatment of cancer. Cancer Invest. 1984;2:203
  12. Vogler WR, Berdel WE, Geller RB, et al.  A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv Exp Med Biol. 1996;416:389
  13. Cagnoni PJ, Jones RB, Bearman SI, et al.  Use of amifostine in bone marrow purging. Semin Oncol. 1996;23:44
  14. Hammert LC, Ball ED. Purging autologous bone marrow with monoclonal antibodies for transplantation in acute myelogenous leukemia. Blood Rev. 1997;11:80
  15. Spellberg B, Schiller GJ. Autologous bone marrow transplantation in acute leukemia. Hematol Oncol Clin North Am. 1999;13:919
  16. Gorin NC, Labopin M, Laporte JP, et al.  Importance of marrow dose on posttransplant outcome in acute leukemia (models derived from patients autografted with mafosfamide-purged marrow at a single institution). Exp Hematol. 1999;27:1822
  17. Ball ED, Wilson J, Phelps V, Neudorf S. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow (results of phase II studies with long-term follow-up). Bone Marrow Transplant. 2000;25:823
  18. Schouten HC, Kvaloy S, Sydes M, Qian W, Fayers PM. The CUP trial (a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)). Ann Oncol. 2000;11:91
  19. Yeager AM, Kaizer H, Santos GW, et al.  Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. 1986;315:141
  20. Santos GW, Saral R, Burns WH, et al.  Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas—Baltimore experiences. Acta Haematol. 1987;78:175
  21. Korbling M, Hunstein W, Fliedner TM, et al.  Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. Blood. 1989;74:1898
  22. Demirer T, Gooley T, Buckner CD, et al.  Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. Bone Marrow Transplant. 1995;15:907
  23. Tamayo E, Herve P. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow. Exp Hematol. 1988;16:97
  24. Domenech J, Georget MT, Gihana E, et al.  Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow. Bone Marrow Transplant. 1992;9:101
  25. Olivieri A, Poloni A, Montanari M, et al.  Pharmacologic bone marrow purging (is there any place for etoposide? In vitro comparison with mafosfamide). J Hematother. 1997;6:137
  26. Lemoli RM, Visani G, Leopardi G, et al.  Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients (a pilot study). Bone Marrow Transplant. 1999;23:235
  27. Poloni A, Leoni P, Curzi L, et al.  Ex vivo pharmacologic purging of leukapheresis collections with nitrogen mustard (amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery). Exp Hematol. 1999;27:1548
  28. Gommerman JL, Berger SA. Protection from apoptosis by steel factor but not interleukin-3 is reversed through blockade of calcium influx. Blood. 1998;91:1891
  29. Soboloff J, Berger SA. Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. J Biol Chem. 2002;277:13812
  30. Corbett EF, Michalak M. Calcium, a signaling molecule in the endoplasmic reticulum?. Trends Biochem Sci. 2000;25:307
  31. Meldolesi J, Pozzan T. The endoplasmic reticulum Ca2+ store (a view from the lumen). Trends Biochem Sci. 1998;23:10
  32. Bian X, Hughes FM, Huang Y, Cidlowski JA, Putney JW. Roles of cytoplasmic Ca2+ and intracellular Ca2+ stores in induction and suppression of apoptosis in S49 cells. Am J Physiol. 1997;272:C1241
  33. Nakagawa T, Zhu H, Morishima N, et al.  Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature. 2000;403:98
  34. Zhang Y, Crump M, Berger SA. Purging of contaminated breast cancer cells from hematopoietic progenitor cell preparations using activation-enhanced cell death. Breast Cancer Res Treat. 2002;72:265
  35. Kanakura Y, Furitsu T, Tsujimura T, et al.  Activating mutations of the c-Kit proto-oncogene in a human mast cell leukemia cell line. Leuk Suppl. 1994;1:S18
  36. Dunn TB, Potter M. A transplantable mast cell neoplasm in the mouse. J Natl Cancer Inst. 1957;18:587
  37. Minden MD, Buick RN, McCulloch EA. Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia. Blood. 1979;54:186
  38. Johnson EA, Brown BW. The Spearman estimator for serial dilution assays. Biometrics. 1961;17:79
  39. Grynkiewcz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440
  40. Gamberucci A, Fulceri R, Benedetti A, Bygrave FL. On the mechanism of action of econazole, the capacitative calcium inflow blocker. Biochem Biophys Res Commun. 1998;248:75
  41. Robertson JD, Orrenius S, Zhivotovsky B. Review (nuclear events in apoptosis). J Struct Biol. 2000;129:346
  42. Martelli AM, Zweyer M, Ochs RL, et al.  Nuclear apoptotic changes (an overview). J Cell Biochem. 2001;82:634
  43. Franzius D, Hoth M, Penner R. Non-specific effects of calcium entry antagonists in mast cells. Pflugers Arch. 1994;428:433
  44. Jan CR, Ho CM, Wu SN, Tseng CJ. Multiple effects of econazole on calcium signaling (depletion of thapsigargin-sensitive calcium store, activation of extracellular calcium influx, and inhibition of capacitative calcium entry). Biochim Biophys Acta. 1999;1448:533
  45. Auber ML, Horwitz LJ, Blaauw A, et al.  Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia. Blood. 1988;71:166
  46. Uckun FM, Ramakrishnan S, Haag D, Houston LL. Ex vivo elimination of lymphoblastic leukemia cells from human marrow by mafosfamide. Leuk Res. 1985;9:83

PII: S0301-472X(02)00893-7

Experimental Hematology
Volume 30, Issue 10 , Pages 1219-1226 , October 2002

Article Tools

* Image Usage & Resolution